Study of autoimmune blistering diseases and their severity measures
Prevalence and Clinical Severity of Autoimmune Blistering Diseases
University of Pennsylvania · NCT02753777
This study is testing how well certain measures of disease severity work for people with autoimmune blistering diseases to see how they relate to quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Pennsylvania (other) |
| Locations | 3 sites (Philadelphia, Pennsylvania and 2 other locations) |
| Trial ID | NCT02753777 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on autoimmune blistering diseases such as pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid. It aims to validate disease severity measures, specifically the Pemphigus Disease Area Index (PDAI) and the Bullous Pemphigoid Disease Area Index (BPDAI), by comparing them with other established severity measures. Participants will also assess their quality of life and may contribute blood samples for further research. The goal is to enhance the understanding of disease severity and its impact on patients' lives.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years diagnosed with pemphigus vulgaris, pemphigus foliaceus, or bullous pemphigoid.
Not a fit: Patients under 18 years old or those without a diagnosis of pemphigus or pemphigoid diseases will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved assessment tools for disease severity, ultimately enhancing treatment strategies for patients with autoimmune blistering diseases.
How similar studies have performed: Other studies have shown success in validating disease severity measures in similar autoimmune conditions, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Gender/Age: Males or females above 18 years old * Diagnosis: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid * Subjects able to give informed consent Exclusion Criteria: * Patients who are under age 18 years. * Patients without pemphigus or pemphigoid diseases * Penn employees * Penn students * Cognitively impaired persons
Where this trial is running
Philadelphia, Pennsylvania and 2 other locations
- Hospital of the University of Pennsylvania, Department of Dermatology — Philadelphia, Pennsylvania, United States (RECRUITING)
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States (RECRUITING)
- University of Pennsylvania, Department of Dermatology — Philadelphia, Pennsylvania, United States (RECRUITING)
Study contacts
- Study coordinator: Victoria P Werth, MD
- Email: werth@pennmedicine.upenn.edu
- Phone: 215-615-2940
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid